New Zealand signs deal with Pfizer, BioNTech for COVID-19 vaccine

Indonesia explores COVID-19 vaccine cooperation with UK Switzerland

With four COVID-19 vaccine candidates in the final stage of clinical trials, China is so far the largest economy supporting the initiative. Some of the candidate manufacturers are Sinovac, Sinopharm, the University of Oxford, AstraZeneca, Novavax, Moderna and others'. These are the Gamaleya Research Institute of Russian Federation, which created the Sputnik V vaccine, Janssen Pharmaceutica of medical giant Johnson and Johnson, and the Sinovac Biotech Co. Across these five countries 20,000 participants will be tested.

The vaccine, developed by the Moscow-based Gamaleya Institute in coordination with the Russian Defence Ministry, is expected to be rolled out to all citizens of the country by October-end.

The US regulator is investigating the side effects.

In a statement, AstraZeneca said: "On 6 September, the standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees and worldwide regulators". But the Medicines Health Regulatory Authority (MHRA) in the United Kingdom confirmed that it was safe to continue the trial in the UK.

It is created to discourage national governments from hoarding COVID-19 vaccines and to focus on first vaccinating the most high-risk people in every country.

Research by Australia's national science agency has found that potential vaccines for COVID-19 would not be affected by how the virus has mutated.

Hua said China leads the world with several vaccines in advanced stages of research and development with ample production capacity.

"There is no indication that vaccines can be a single solution to the COVID-19 pandemic". According to the United Nations, the mucosal vaccine is a very good idea.

According to the information received, genetic engineering has been used for this nasal spray which will eliminate the NS1 protein and enter the domain receptor bound to the spike protein of SARS-CoV-2 virus.

She explained the clinical trials may last for three months and, "if all goes well, the vaccine may be made available as early as January next year" for the country. Yuen said that it works effectively in animals. She told The Times that she thought there was a high chance that the trial would work, "based on other things that we have done with this type of vaccine".

"We need to be proactive and look for every way we can to secure the vaccine quickly", Nakorn said in a phone interview Thursday.

Washington has pumped billions of dollars in efforts to develop a vaccine. "Since the Philippines is one of countries that is now studying the vaccine, we want to be given updates on its trials to give our people the information and to help to facilitate cooperation between the two countries to ensure its availability in the country if the tests go well at the earliest possible time", Robes said. "To that end, we have solemnly pledged to make vaccines developed and deployed by China a global public good, which will be provided to developing countries as a priority". One of their goals is to stop the growth of germs in the nose, a point from which it can spread to other parts of the body and to other people.

"The government, through the Health Ministry, will procure vaccines from AstraZeneca in a contract for 100 million doses", Airlangga said in a Sunday webinar held by the Association of the Gadjah Mada University Alumni.

"We have set aside $66.3 million for medical supplies and infrastructure to ensure New Zealand is ready to launch a Covid-19 Immunisation Programme as soon as we have a safe and effective vaccine".